Reig Jofre launches sleep supplement in France

28 Jan 2018

Forté Pharma's new nutritional supplement combines natural extracts: valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

Forté Pharma, Reig Jofre’s nutritional supplements line, has launched Forté Nuit 8h in France, its home market. The new nutritional supplement extends the company's health range and represents the natural alternative to help to fight sleep disorders.

Reig Jofre launches sleep supplement in France

Forté Nuit 8h improves the latency time; it also provides quality rest for 8 hours, without drowsiness or side effects upon awakening and without causing dependence.

Forté Nuit 8h acts with a double effect thanks to its natural formula, the optimal dose of its ingredients and its original bilayer tablets format, which provides an immediate effect through the rapid melatonin release that favors the first phase of the sleep cycle, as well as a long-acting effect thanks to the combination of natural extracts, valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

Forté Pharma is planning Forté Nuit 8h’s international expansion and will start its marketing in Belgium during the first quarter of 2018.

Regarding the Spanish market, Forté Pharma plans to continue the development of the weight control segment during the first half of the year and to boost the rest of the categories in the second half.

Forte Pharma's portfolio is organized into four segments: energy (35% of its total sales), slimming (30%), health (22%) and beauty (13%) as at the end of September 2017.

At present, the marketing of Forte Pharma products is conducted mostly in Europe through its own sales network. Forte Pharma’s home market - France - is still the first market of the brand, which accounted for 67% of sales.

Read More

Related tags

Market News

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more